Merck Says New Phase 3 Data Indicate Stable Safety Profile for Enflonsia
MT Newswires Live
Yesterday
Merck & Co (MRK) said Thursday that new data from a phase 3 trial of Enflonsia in infants and children at increased risk for severe respiratory syncytial virus disease showed a safety profile consistent with that observed in the first season of the study.
The company said the findings reinforce the drug's potential as a preventive option for vulnerable pediatric populations.
Merck plans to submit the second season data set to the US Food and Drug Administration.
The drug is currently approved for use in the US, Canada and other countries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.